Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $648.3 million.

  • Bicycle Therapeutics' Cash & Equivalents fell 27.22% to $648.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648.3 million, marking a year-over-year decrease of 27.22%. This contributed to the annual value of $879.5 million for FY2024, which is 67.07% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Cash & Equivalents of $648.3 million as of Q3 2025, which was down 10.14% from $721.5 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Cash & Equivalents registered a high of $961.4 million during Q2 2024, and its lowest value of $195.9 million during Q1 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $648.3 million (2025), whereas its average is $644.0 million.
  • As far as peak fluctuations go, Bicycle Therapeutics' Cash & Equivalents spiked by 222.58% in 2021, and later fell by 27.88% in 2023.
  • Over the past 5 years, Bicycle Therapeutics' Cash & Equivalents (Quarterly) stood at $438.7 million in 2021, then dropped by 22.69% to $339.2 million in 2022, then spiked by 55.22% to $526.4 million in 2023, then soared by 67.07% to $879.5 million in 2024, then dropped by 27.22% to $648.3 million in 2025.
  • Its last three reported values are $648.3 million in Q3 2025, $721.5 million for Q2 2025, and $793.0 million during Q1 2025.